Tobramycin inhalation powder in cystic fibrosis patients: Response by age group

Respiratory Care

Volumn 59, Issue 3, 2014, Pages 388-398

  Geller, David E ^a   Nasr, Samya Z ^b   Piggott, Simon ^c   He, Ellie ^c   Angyalosi, Gerhild ^c   Higgins, Mark ^c  

^a FLORIDA STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Age groups; Cystic fibrosis; Drug delivery systems; Pseudomonas aeruginosa; Tobramycin inhalation powder; Topical anti infective agents

Indexed keywords

TOBRAMYCIN; ANTIINFECTIVE AGENT;

ADOLESCENT; ADULT; AGE; ARTICLE; CHILD; CLINICAL ASSESSMENT; CLINICAL EVALUATION; COUGHING; CYSTIC FIBROSIS; DRUG EFFICACY; DRUG SAFETY; DRY POWDER INHALER; DYSGEUSIA; DYSPHONIA; FEMALE; FORCED EXPIRATORY VOLUME; HEMOPTYSIS; HOSPITALIZATION; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; OROPHARYNX PAIN; PATIENT SATISFACTION; PNEUMONIA; POST HOC ANALYSIS; PSEUDOMONAS INFECTION; RANDOMIZED CONTROLLED TRIAL; RHINORRHEA; SCHOOL CHILD; SINUSITIS; SPIROMETRY; STRUCTURED QUESTIONNAIRE; UPPER RESPIRATORY TRACT INFECTION; YOUNG ADULT; CLINICAL TRIAL; COMPLICATION; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG EFFECTS; INHALATIONAL DRUG ADMINISTRATION; ISOLATION AND PURIFICATION; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHYSIOLOGY; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

ADMINISTRATION, INHALATION; ADOLESCENT; AGE FACTORS; ANTI-BACTERIAL AGENTS; CHILD; CONFIDENCE INTERVALS; CYSTIC FIBROSIS; DRY POWDER INHALERS; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; PATIENT SATISFACTION; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; TOBRAMYCIN; YOUNG ADULT;

EID: 84888992940     PISSN: 00201324     EISSN: 19433654     Source Type: Journal    
DOI: 10.4187/respcare.02264     Document Type: Article

References (31)

1. Høiby N, Frederiksen B, Pressler T. Eradication of early Pseudomonas aeruginosa infection. J Cyst Fibros 2005;4(Suppl 2):49-54.
2. Flume PA, O'Sullivan BP, Robinson KA, Goss CH, Mogayzel PJ Jr, Willey-Courand DB, et al; Cystic Fibrosis Foundation; Pulmonary Therapies Committee. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2007;176(10):957-969.
3. Daniels T, Goodacre L, Sutton C, Pollard K, Conway S, Peckham D. Accurate assessment of adherence: self-report and clinician report vs electronic monitoring of nebulizers. Chest 2011;140(2):425-432.
4. Dodd ME, Webb AK. Understanding non-compliance with treatment in adults with cystic fibrosis. J R Soc Med 2000;93(Suppl 38):2-8.
5. Sawicki GS, Sellers DE, Robinson WM. High treatment burden in adults with cystic fibrosis: challenges to disease self-management. J Cyst Fibros 2009;8(2):91-96.
6. Briesacher BA, Quittner AL, Saiman L, Sacco P, Fouayzi H, Quittell LM. Adherence with tobramycin inhaled solution and health care utilization. BMC Pulm Med 2011;11:5. DOI: 10.1186/1471-2466-11-5.
7. Eakin MN, Bilderback A, Boyle MP, Mogayzel PJ, Riekert KA. Longitudinal association between medication adherence and lung health in people with cystic fibrosis. J Cyst Fibros 2011;10(4):258-264.
8. Sawicki GS, Signorovitch JE, Zhang J, Latremouille-Viau D, von Wartburg M, Wu EQ, Shi L. Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution. Pediatr Pulmonol 2012;47(1):44-52.
9. Murphy TD, Anbar RD, Lester LA, Nasr SZ, Nickerson B, VanDevanter DR, Colin AA. Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease. Pediatr Pulmonol 2004;38(4):314-320.
10. Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, et al; Cystic Fibrosis Inhaled Tobramycin Study Group. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 1999;340(1):23-30.
11. vanDyke R, McPhail GL, Kahill L, Fenchel M, Carle A, Amin R, et al. Effects of long-term tobramycin on lung function decline in children with cystic fibrosis (abstract #328). Pediatr Pulmonol 2011; 46(Suppl 34):330.
12. Konstan MW, Flume PA, Kappler M, Chiron R, Higgins M, Brockhaus F, et al. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: the EAGER trial. J Cyst Fibros 2011;10(1):54-61.
13. Harrison MJ, McCarthy M, Fleming C, Hickey C, Shortt C, Eustace JA, et al. Improved adherence, tolerability and low discontinuation rate in a prospective real world study with tobramycin inhaled powder (TIP) compared to tobramycin inhaled solution (TIS) in cystic fibrosis (CF). Irish J Med Sci 2012;181(Suppl 10):S403.
14. Geller DE, Weers J, Heuerding S. Development of an inhaled drypowder formulation of tobramycin using PulmoSphere technology. J Aerosol Med Pulm Drug Deliv 2011;24(4):175-182.
15. Newhouse MT, Hirst PH, Duddu SP, Walter YH, Tarara TE, Clark AR, et al. Inhalation of a dry powder tobramycin PulmoSphere formulation in healthy volunteers. Chest 2003;124(1):360-366.
16. Geller DE, Konstan MW, Smith J, Noonberg SB, Conrad C. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety. Pediatr Pulmonol 2007;42(4):307-313.
17. Geller DE. Comparing clinical features of the nebulizer, metereddose inhaler, and dry powder inhaler. Respir Care 2005;50(10):1313-1321.
18. Virchow JC, Crompton GK, Dal Negro R, Pedersen S, Magnan A, Seidenberg J, et al. Importance of inhaler devices in the management of airway disease. Respir Med 2008;102(1):10-19.
19. Konstan MW, Byard PJ, Hoppel CL, Davis PB. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 1995;332(13): 848-854.
20. Retsch-Bogart GZ, Quittner AL, Gibson RL, Oermann CM, McCoy KS, Montgomery AB, et al. Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis. Chest 2009;135(5): 1223-1232.
21. Knudson RJ, Lebowitz MD, Holberg CJ, Burrows B. Changes in the normal maximal expiratory flow-volume curve with growth and aging. Am Rev Respir Dis 1983;127(6):725-734.
22. Atkinson MJ, Sinha A, Hass SL, Colman SS, Kumar RN, Brod M, et al. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes 2004;2:12. DOI: 10.1186/1477-7525-2-36.
23. Tiddens HA, Geller DE, Challoner P, Speirs RJ, Kesser KC, Overbeek SE, et al. Effect of dry powder inhaler resistance on the inspiratory flow rates and volumes of cystic fibrosis patients of six years and older. J Aerosol Med 2006;19(4):456-465.
24. Mazurek H, Lenoir G, Pelikan L, Geidel C, Bolbas K, Antipkin Y, et al. Head-to-head comparison of two inhaled tobramycin solutions in cystic fibrosis (CF) patients with chronic Pseudomonas aeruginosa (Pa) infection. J Cyst Fibros 2011;10(Suppl 1):28S.
25. Konstan MW, Wagener JS, Pasta DJ, Millar SJ, Jacobs JR, Yegin A, et al; Scientific Advisory Group and Investigators and Coordinators of Epidemiologic Study of Cystic Fibrosis. Clinical use of dornase alpha is associated with a slower rate of FEV1 decline in cystic fibrosis. Pediatr Pulmonol 2011;46(6):545-553.
26. Retsch-Bogart GZ, McKoy KS, Oermann CM, Lewis S, Bresnik M, Assael BM. Aztreonam for inhalation solution (AZLI) clinical development program: combined pediatric experience (abstract #305). Pediatr Pulmonol 2011;46(Suppl 34):322.
27. Aitken ML, Flume PA, Geller DE, Lapey A, Zuckerman J, De Boeck, K, et al. Efficacy and safety by age group from the Phase III studies of bronchitol (inhaled mannitol) in patients with CF. Pediatr Pulmonol 2011;46(Suppl 34):P236.
28. Zapletal A, Houstek J, Samanek M, Vavrova V, Srajer J. Lung function abnormalities in cystic fibrosis and changes during growth. Bull Eur Physiopathol Respir 1979;15(4):575-592.
29. Hart N, Polkey MI, Clément A, Boulé M, Moxham J, Lofaso F, et al. Changes in pulmonary mechanics with increasing disease severity in children and young adults with cystic fibrosis. Am J Respir Crit Care Med 2002;166(1):61-66.
30. Ballmann M, Smyth A, Geller DE. Therapeutic approaches to chronic cystic fibrosis respiratory infections with available, emerging aerosolized antibiotics. Respir Med 2011;105(Suppl 2):S2-S8.
31. Hurt K, Bilton D. Inhaled mannitol for the treatment of cystic fibrosis. Expert Rev Respir Med 2012;6(1):19-26.